Novel Manufacturing Technologies for the Production of Patient-Centric Drug Products

The dose forms that the pharmaceutical industry provides to elderly patients are far from ideal in many regards, and recent trends in the industry have emphasized the potential benefits that may be obtained by emphasizing the patient’s needs in the formulation and manufacturing design process (as noted by Van Riet-Nales et al. [1], Stegemann et al. [2]), i.e., “age-related formulations.” Naturally, the physical and chemical properties of the active pharmaceutical ingredient (or “API”) constrain the set of viable potential dose forms, and biological factors, which have a significant influence on oral drug absorption in a wide range of patient groups, are critical aspects of formulation and manufacturing process selection. The development of an oral drug product that can be manufactured using a robust process is a critical element both of providing a suitable medicine of appropriate quality to the patient and a commercial return to the pharmaceutical company. Within this highly constrained design problem, it may be possible for the industry to develop new approaches by thinking creatively about the entire set of highly connected formulation and manufacturing challenges, and to remodel factory operations or, potentially, whole supply chains. Regulators, and the pharmaceutical companies themselves, have historically taken a conservative approach to novel manufacturing technologies that may offer quality and cost advantages over the conventional supply chain paradigms. Innovations, in the examples discussed below, will not be adopted rapidly, as change on such a scale occurs slowly. However, it is interesting to consider the benefits that such drug product manufacturing innovations might provide to patients. In recent years, regulators and the industry have sought to develop such approaches that not only offer patient benefits but that do so at commercially acceptable costs, and which are designed using robust and established manufacturing engineering principles.

[1]  D. Grobbee,et al.  The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. , 2013, American heart journal.

[2]  Maryann M Fulton,et al.  Polypharmacy in the elderly: A literature review , 2005, Journal of the American Academy of Nurse Practitioners.

[3]  C. Cannon Can the polypill save the world from heart disease? , 2009, The Lancet.

[4]  J. M. Casado The history of geriatric medicine. The present: Problems and opportunities , 2012 .

[5]  D. V. van Riet-Nales,et al.  Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review. , 2010, Clinical therapeutics.

[6]  M. Orlu-Gul,et al.  ommentary eeting commentary — “ Medicines for older adults : Learning from ractice to develop patient centric drug products ” , 2013 .

[7]  Hiroto Ito,et al.  What Should We Do to Improve Patients' Adherence? , 2013 .

[8]  C. Tuleu,et al.  Public engagement workshop: how to improve medicines for older people? , 2014, International journal of pharmaceutics.

[9]  C. Tuleu,et al.  Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations , 2014, Drugs.

[10]  E. McAuley,et al.  Predictors of adherence to behavior change interventions in the elderly. , 2000, Controlled clinical trials.

[11]  S. Yusuf,et al.  The Indian Polycap Study (TIPS) – Authors' reply , 2009, The Lancet.

[12]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[13]  J. Baeyens,et al.  Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models , 2014, Zeitschrift für Gerontologie und Geriatrie.

[14]  Francesca Cerreta,et al.  Adherence measurement systems and technology for medications in older patient populations , 2012 .

[15]  D. Wald,et al.  The Polypill in the prevention of cardiovascular disease. , 2011, Preventive medicine.

[16]  Allan Clarke,et al.  Development of Liquid Dispensing Technology for the Manufacture of Low Dose Drug Products , 2017 .

[17]  R. Doughty,et al.  IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care. , 2011, Contemporary clinical trials.

[18]  A. Zimmer,et al.  Geriatric drug therapy: Neglecting the inevitable majority , 2010, Ageing Research Reviews.

[19]  Jack Y. Zheng Formulation and Analytical Development for Low-Dose Oral Drug Products , 2009 .

[20]  J. Seville,et al.  A comparative study of compaction properties of binary and bilayer tablets , 2009 .

[21]  Mridula Nair,et al.  Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable , 2007, Expert opinion on drug safety.

[22]  M. Vaduganathan,et al.  Expanding the scope of the "polypill" to heart failure. , 2013, Journal of cardiac failure.

[23]  S. Kagan,et al.  Adherence and oral agents with older patients. , 2011, Seminars in oncology nursing.

[24]  Jennifer G. Robinson,et al.  A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. , 2005, The American journal of cardiology.

[25]  S. Wollowitz Managing high‐potency active pharmaceutical ingredients—A drug sponsor's guide , 2010 .

[26]  Jack Y. Zheng Challenges and Strategies in Formulation Development of Oral Solid Low‐Dose Drug Products , 2008 .

[27]  Yu Heng Kwan,et al.  Medication adherence in the elderly , 2016 .

[28]  R. Sulkava,et al.  Patterns of Drug Use and Factors Associated with Polypharmacy and Excessive Polypharmacy in Elderly Persons , 2009, Drugs & aging.

[29]  I. Gavras,et al.  Fixed-drug combinations as first-line treatment for hypertension. , 2006, Progress in cardiovascular diseases.

[30]  M. Law,et al.  The Indian Polycap Study (TIPS) , 2009, The Lancet.

[31]  K. Masaki,et al.  Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. , 2012, Journal of the American Medical Directors Association.

[32]  A. Mohammed,et al.  The impact of ageing on the barriers to drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[33]  S. Leeder,et al.  Duration of initial antihypertensive prescription and medication adherence: a cohort study among 203,259 newly diagnosed hypertensive patients. , 2015, International journal of cardiology.

[34]  J. Remon,et al.  Tablet-splitting: a common yet not so innocent practice. , 2011, Journal of advanced nursing.

[35]  V. Fuster,et al.  The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. , 2011, American heart journal.

[36]  S. Jain,et al.  Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance , 2001, Postgraduate medical journal.

[37]  C. Sharkness,et al.  The patient's view of hypertension and compliance. , 1992, American journal of preventive medicine.

[38]  G. Sergi,et al.  Polypharmacy in the Elderly , 2011, Drugs & aging.

[39]  Victor E. Kane,et al.  Process Capability Indices , 1986 .

[40]  Betty L. Elder,et al.  The Role of a Self-Directed Technology to Improve Medication Adherence in Heart Failure Patients , 2014 .

[41]  Michael J Blaha,et al.  Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis). , 2014, Journal of the American College of Cardiology.

[42]  J Breitkreutz,et al.  Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. , 2012, International journal of pharmaceutics.

[43]  L. Treiber,et al.  Intervening at the Intersection of Medication Adherence and Health Literacy , 2014 .

[44]  Michel C. A. Klein,et al.  Intelligent mobile support for therapy adherence and behavior change , 2014, J. Biomed. Informatics.

[45]  V. Fuster,et al.  Polypill and global cardiovascular health strategies. , 2011, Seminars in thoracic and cardiovascular surgery.

[46]  R. Balkrishnan,et al.  Predictors of medication adherence in the elderly. , 1998, Clinical therapeutics.

[47]  L. Ring,et al.  "I don't know how many of these [medicines] are necessary.." - a focus group study among elderly users of multiple medicines. , 2009, Patient education and counseling.

[48]  Helen E. Smith,et al.  Measuring the adherence to medication of elderly patients with heart failure: is there a gold standard? , 2010, International journal of cardiology.

[49]  V. Fuster,et al.  A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. , 2014, Journal of the American College of Cardiology.

[50]  Upkar Varshney,et al.  Smart medication management system and multiple interventions for medication adherence , 2013, Decis. Support Syst..

[51]  A. Rodgers,et al.  The Efficacy and Tolerability of ‘Polypills’: Meta-Analysis of Randomised Controlled Trials , 2012, PloS one.

[52]  S. Yusuf,et al.  Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial , 2009, The Lancet.